Sign in
CYBN Stock Price, Chart, Stats & News
Cybin Inc.
Save
Cybin Inc. (CYBN) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
CYBN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -54.87% |
ROE | -51.79% |
D/E | 0.21x |
Interest coverage ratio | – |
CYBN valuation
P/E | – |
P/S | – |
P/B | 2.00x |
P/CF | -2.48x |
P/FCF | -5.02x |
P/OCF | -2.48x |
PEG | -0.08x |
EV multiple | -5.33x |
About
Cybin Inc. is a biopharmaceutical firm dedicated to pioneering treatments that leverage psychedelic compounds. Its research and development portfolio encompasses several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine designed to alleviate anxiety conditions; and CYB005, a phenethylamine derivative aimed at combating neuroinflammation. Beyond its drug pipeline, Cybin has also conceived EMBARK, an innovative form of psychotherapy enhanced by psychedelics.
Similar securities
Based on sector and market capitalization
Report issue